Tookad: Withdrawal of the application to change the marketing authorisation



Steba biotech S.A. withdrew its application to modify the grading system and biopsy requirements for use of Tookad in the treatment of prostate cancer and extend its use from low-risk to intermediate-risk patients.

The company withdrew the application on 14 December 2021.

Key facts

Product number
Date of issue of market authorisation valid throughout the European Union (if applicable)
International non-proprietary name (INN) or common name
  • padeliporfin
Active substance
  • padeliporfin di-potassium
Date of withdrawal
Company making the application
STEBA Biotech S.A
Withdrawal type

Related content

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

How useful was this page?

Add your rating